Molecular modeling indicated strong binding affinities of ER to both ABCB1 and ABCG2 proteins, supporting the hypothesis that Erastin interacts directly with ABC transporters, modulating their activity and thereby enhancing chemotherapeutic drug retention in resistant tumor cells. This evidence concerns the gene ABCG2 and neoplasm.